Safety and Efficacy Study of NUV-1511 in Adult Patients With Advanced Solid Tumors
NUV-1511-01 is a first-in human, open- label, Phase 1/2 to evaluate the safety and efficacy of NUV-1511 in patients with advanced solid tumors. The Phase 1 portion include patients with advanced solid tumors and is designed to determine the safety and the tolerability of doses of NUV-1511. In Phase 2, NUV-1511 will be given to determine the efficacy of patients with advanced solid tumors.
Advanced Solid Tumor|HER2-negative Breast Cancer|Metastatic Castration-resistant Prostate Cancer (mCRPC)|Pancreatic Cancer|Platinum-resistant Ovarian Cancer (PROC)
DRUG: NUV-1511
Phase 1: Assess safety and tolerability of NUV-1511 in advanced solid tumors, Number of patients with dose limiting toxicities, treatment emergent adverse events (TEAE) and serious adverse events (SAE) and laboratory abnormalities, First 28 days of dosing (DLT evaluation period)|Phase 1: Identify recommended dosing schedule(s) and corresponding Phase 2 dose(s) (RP2D(s)), Number of patients with DLTs, TEAEs and SAEs and laboratory abnormalities, First 28 days of dosing (DLT evaluation period)|Phase 2: Evaluate the efficacy of NUV-1511 in advanced solid tumors and selected tumor type(s), Efficacy measures may include tumor assessments, as assessed by CT scans, PET/CT, whole body bone scan and MRI, From date of enrollment to date of disease progression, withdrawal of consent, or initiation of subsequent anticancer treatment or up to a period of 5 years, whichever occurs first|Phase 2: Confirm the optimal NUV-1511 dose level/schedule for further development, Overall response rate per RECIST 1.1 (Composite response rate for mCRPC patients only, if enrolled in Phase 2), Periodic efficacy assessments from date of enrollment to date of disease progression, withdrawal of consent, or initiation of subsequent anticancer treatment or up to a period of 5 years, whichever occurs first|Phase 2: Confirm the optimal NUV-1511 target tumor types for further development, Overall response rate per RECIST 1.1 (Composite response rate for mCRPC patients only, if enrolled in Phase 2), Periodic efficacy assessments from date of enrollment to date of disease progression, withdrawal of consent, or initiation of subsequent anticancer treatment or up to a period of 5 years, whichever occurs first
Phase 1: Explore preliminary efficacy of NUV-1511, Overall response rate and duration of response per RECIST 1.1. Efficacy measures may include tumor assessments, as assessed by CT scans, PET/CT, whole body bone scan and MRI., From date of enrollment to date of disease progression, withdrawal of consent, or initiation of subsequent anticancer treatment or up to a period of 5 years, whichever occurs first|Phase 1: Explore preliminary efficacy of NUV-1511, Overall response rate and duration of response per composite response rate (for mCRPC). Efficacy measures may include tumor assessments, as assessed by CT scans, PET/CT, whole body bone scan and MRI., From date of enrollment to date of disease progression, withdrawal of consent, or initiation of subsequent anticancer treatment or up to a period of 5 years, whichever occurs first|Phase 1: Explore preliminary efficacy of NUV-1511, Overall response rate and duration of response per response rates in specific disease markers. Efficacy measures may include tumor assessments, as assessed by CT scans, PET/CT, whole body bone scan and MRI., From date of enrollment to date of disease progression, withdrawal of consent, or initiation of subsequent anticancer treatment or up to a period of 5 years, whichever occurs first|Characterize the PK profile of NUV-1511, Parameters include, but not limited to, maximum observed plasma concentration (Cmax), Periodic PK sample collection from date of enrollment to date of disease progression, withdrawal of consent, or initiation of subsequent anticancer treatment or up to a period of 5 years, whichever occurs first.|Characterize the PK profile of NUV-1511, Parameters include, but not limited to, area under the plasma concentration-time curve (AUC), Periodic PK sample collection from date of enrollment to date of disease progression, withdrawal of consent, or initiation of subsequent anticancer treatment or up to a period of 5 years, whichever occurs first.|Phase 2: Further evaluate the safety and efficacy of NUV-1511, Incidence of TEAEs and SAEs, Ongoing monitoring of safety and efficacy from date of enrollment to date of disease progression, withdrawal of consent, or initiation of subsequent anticancer treatment or up to a period of 5 years, whichever occurs first|Phase 2: Further evaluate the safety and efficacy of NUV-1511, Laboratory abnormalities, Ongoing monitoring of safety and efficacy from date of enrollment to date of disease progression, withdrawal of consent, or initiation of subsequent anticancer treatment or up to a period of 5 years, whichever occurs first|Phase 2: Further evaluate the safety and efficacy of NUV-1511, Duration of response, Ongoing monitoring of safety and efficacy from date of enrollment to date of disease progression, withdrawal of consent, or initiation of subsequent anticancer treatment or up to a period of 5 years, whichever occurs first|Phase 2: Further evaluate the safety and efficacy of NUV-1511, Clinical best response, Ongoing monitoring of safety and efficacy from date of enrollment to date of disease progression, withdrawal of consent, or initiation of subsequent anticancer treatment or up to a period of 5 years, whichever occurs first|Phase 2: Further evaluate the safety and efficacy of NUV-1511, Progression free survival, Ongoing monitoring of safety and efficacy from date of enrollment to date of disease progression, withdrawal of consent, or initiation of subsequent anticancer treatment or up to a period of 5 years, whichever occurs first|Phase 2: Further evaluate the safety and efficacy of NUV-1511, Overall survival, Ongoing monitoring of safety and efficacy from date of enrollment to date of disease progression, withdrawal of consent, or initiation of subsequent anticancer treatment or up to a period of 5 years, whichever occurs first|Phase 2: Further evaluate the safety and efficacy of NUV-1511, PK exposure-response modeling, which includes measuring plasma concentration versus overall response rate, Ongoing monitoring of safety and efficacy from date of enrollment to date of disease progression, withdrawal of consent, or initiation of subsequent anticancer treatment or up to a period of 5 years, whichever occurs first|Phase 2: Further evaluate the safety and efficacy of NUV-1511, PK exposure-response modeling, which includes measuring plasma concentration versus progression free survival, Ongoing monitoring of safety and efficacy from date of enrollment to date of disease progression, withdrawal of consent, or initiation of subsequent anticancer treatment or up to a period of 5 years, whichever occurs first|Phase 2: Further evaluate the safety and efficacy of NUV-1511, PK exposure-response modeling, which includes measuring plasma concentration versus treatment emergent adverse events and serious adverse events., Ongoing monitoring of safety and efficacy from date of enrollment to date of disease progression, withdrawal of consent, or initiation of subsequent anticancer treatment or up to a period of 5 years, whichever occurs first|Phase 2: Further evaluate the safety and efficacy of NUV-1511, Response rates in disease-specific markers, Ongoing monitoring of safety and efficacy from date of enrollment to date of disease progression, withdrawal of consent, or initiation of subsequent anticancer treatment or up to a period of 5 years, whichever occurs first
Phase 1 and Phase 2: Evaluate biomarkers potentially related to NUV-1511 anti-tumor activity via ctDNA and tumor tissue analysis, Blood sample for exploratory analysis of circulating DNA, Ongoing monitoring of safety and efficacy from date of enrollment to date of disease progression, withdrawal of consent, or initiation of subsequent anticancer treatment or up to a period of 5 years, whichever occurs first|Phase 1 and Phase 2: Evaluate biomarkers potentially related to NUV-1511 anti-tumor activity via ctDNA and tumor tissue analysis, Blood sample for exploratory analysis of gene expression (including that of hormone receptors and efflux transporters), Ongoing monitoring of safety and efficacy from date of enrollment to date of disease progression, withdrawal of consent, or initiation of subsequent anticancer treatment or up to a period of 5 years, whichever occurs first|Phase 1 and Phase 2: Evaluate biomarkers potentially related to NUV-1511 anti-tumor activity, Tumor biopsy for exploratory analysis of tumor genome, Ongoing monitoring of safety and efficacy from date of enrollment to date of disease progression, withdrawal of consent, or initiation of subsequent anticancer treatment or up to a period of 5 years, whichever occurs first|Phase 1 and Phase 2: Evaluate biomarkers potentially related to NUV-1511 anti-tumor activity, Tumor biopsy for exploratory analysis of epigenome, Ongoing monitoring of safety and efficacy from date of enrollment to date of disease progression, withdrawal of consent, or initiation of subsequent anticancer treatment or up to a period of 5 years, whichever occurs first|Phase 1 and Phase 2: Evaluate biomarkers potentially related to NUV-1511 anti-tumor activity, Tumor biopsy for exploratory analysis of gene expression, Ongoing monitoring of safety and efficacy from date of enrollment to date of disease progression, withdrawal of consent, or initiation of subsequent anticancer treatment or up to a period of 5 years, whichever occurs first|Phase 1 and Phase 2: Explore pharmacogenetic profiling that may be potentially predictive of NUV-1511 antitumor activity or toxicity, Identification of genetic factors that predict toxicity, Blood and tumor biopsy collection at the time of enrollment|Phase 1 and Phase 2: Explore pharmacogenetic profiling that may be potentially predictive of NUV-1511 antitumor activity or toxicity, Identification of genetic factors that predict anti-tumor activity, Blood and tumor biopsy collection at the time of enrollment|Phase 1 and Phase 2: Explore pharmacogenetic profiling that may be potentially predictive of NUV-1511 antitumor activity or toxicity, Identification of genetic factors that predict metabolism of NUV-1511, Blood and tumor biopsy collection at the time of enrollment|Evaluate drug exposure-response relationship, PK exposure response modeling which includes measuring PK exposure versus efficacy, Periodic PK sample collection through disease progression, withdrawal of consent, or initiation of subsequent anticancer treatment or up to a period of 5 years, whichever occurs first|Evaluate drug exposure-response relationship, PK exposure response modeling which includes measuring PK exposure versus safety, Periodic PK sample collection through disease progression, withdrawal of consent, or initiation of subsequent anticancer treatment or up to a period of 5 years, whichever occurs first
NUV-1511-01 is a first-in human, open- label, Phase 1/2 to evaluate the safety and efficacy of NUV-1511 in patients with advanced solid tumors. The Phase 1 portion include patients with advanced solid tumors and is designed to determine the safety and the tolerability of doses of NUV-1511. In Phase 2, NUV-1511 will be given to determine the efficacy of patients with advanced solid tumors.